封面
市場調查報告書
商品編碼
1615410

吉米沙星市場:按形式、適應症和銷售管道- 全球預測 2025-2030

Gemifloxacin Market by Form (Solution, Tablet), Indication (Respiratory Infection, Urinary Tract Infection), Sales Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年吉米沙星市值為7.0559億美元,預計2024年將達到7.4101億美元,複合年成長率為4.88%,預計到2030年將達到9.8509億美元。

吉米沙星是一種Fluoroquinolones抗生素,主要用於治療細菌感染疾病,特別是呼吸道感染疾病,如肺炎、支氣管炎和鼻竇炎。它們的範圍和效用取決於它們對其他抗生素抗藥性的革蘭氏陰性和革蘭氏陽性病原體的有效性。因此,在傳統抗生素無效的情況下,需要吉米沙星作為先進的治療選擇。吉米沙星的應用涵蓋製藥和醫療領域,特別是在醫院和門診診所。最終用途包括直接配製和納入更廣泛的抗菌治療制度。市場洞察表明,由於呼吸道疾病的增加以及對抗多重抗藥性細菌的興趣日益濃厚,預計將出現強勁成長。隨著非專利市場因專利到期擴大,擁有先進醫療基礎設施的新興經濟體的商機已經成熟。專注於最佳化遞送機制的研究投資,例如緩釋性和聯合治療,為業務成長提供了肥沃的土壤。然而,嚴格的法律規範和與Fluoroquinolones抗生素相關的潛在副作用等限制限制了其在某些地區的使用。抗藥性細菌的發展以及來自大環內酯類和Ketolide等替代療法的競爭給市場擴張帶來了進一步的挑戰。創新者可以利用對病原體抗藥性的遺傳見解來開發個人化醫療方法,以最大限度地提高吉米沙星的有效性。此外,市場動態揭示了更環保、更永續的製造流程的趨勢,為企業領導者提供了將綠色技術融入生產的機會,以吸引環保意識的相關人員。總體而言,駕馭這個市場需要將合規性、創新研究和對人口健康趨勢的敏銳洞察進行策略結合。隨著呼吸系統疾病盛行率的不斷上升,特別是在人口老化中,擴展到服務不足的地區可以帶來顯著的好處。採取此類措施將有助於維持市場相關性並應對消費者期望和監管環境的變化。

主要市場統計
基準年[2023] 70559萬美元
預計年份 [2024] 74101萬美元
預測年份 [2030] 98509萬美元
複合年成長率(%) 4.88%

市場動態:揭示快速發展的吉米沙星市場的關鍵市場洞察

供需的動態交互作用正在改變吉米沙星市場。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於其廣泛的抗菌特性,對吉米沙星的需求不斷增加
    • 支持醫療基礎設施改革以改善抗生素的獲取
  • 市場限制因素
    • 因安全問題而召回產品
  • 市場機會
    • 吉米沙星生產技術不斷進步
    • 製藥公司與學術/研究機構之間的夥伴關係
  • 市場問題
    • 仿冒品盛行及生產問題

波特五力:駕馭吉米沙星市場的策略工具

波特五力:框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解吉米沙星市場的外部影響

外部宏觀環境因素在塑造吉米沙星市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並幫助他們做出積極主動的決策。

市場佔有率分析:了解吉米沙星市場的競爭格局

對吉米沙星市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、細分和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣:吉米沙星市場供應商的績效評估

FPNV定位矩陣是評估吉米沙星市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商,從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商,以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議:繪製吉米沙星市場的成功之路

對於旨在加強在全球市場的影響力的公司來說,對吉米沙星市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率:對當前市場環境的詳細審查,主要企業的廣泛資料,評估他們在市場中的影響力和整體影響力。

2. 市場開拓:辨識新興市場的成長機會,評估現有細分市場的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品和地區提供最佳投資機會?

3.塑造市場的關鍵技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 廣譜抗菌特性增加了對吉米沙星的需求
      • 對衛生基礎設施進行支持性改革,以增加抗生素的獲取
    • 抑制因素
      • 因安全問題而召回產品
    • 機會
      • 吉米沙星生產技術不斷進步
      • 製藥公司與學術或研究機構之間的合作關係
    • 任務
      • 仿冒品的盛行與製造問題
  • 市場區隔分析
    • 形式:吉米沙星錠劑因其方便常規門診病人使用而越來越受歡迎
    • 分銷管道:根據醫療專業人員的診斷和處方,透過醫院藥房擴大吉米沙星的獲取範圍
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 吉米沙星市場:依形式

  • 介紹
  • 解決方案
  • 錠劑

第7章 吉米沙星市場:依適應症分類

  • 介紹
  • 呼吸道感染疾病
  • 尿道感染

第8章 吉米沙星市場:按分銷管道

  • 介紹
  • 醫院藥房
  • 網路商店
  • 零售藥房

第9章 美洲吉米沙星市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太吉米沙星市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲吉米沙星市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Sun Pharma 與太郎製藥簽署收購協議
  • 戰略分析和建議

公司名單

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma Limited
  • BASF SE
  • Emcure Pharmaceuticals Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Orchid Chemicals & Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-5D693B46C82C

The Gemifloxacin Market was valued at USD 705.59 million in 2023, expected to reach USD 741.01 million in 2024, and is projected to grow at a CAGR of 4.88%, to USD 985.09 million by 2030.

Gemifloxacin is a fluoroquinolone antibiotic primarily used to treat bacterial infections, specifically respiratory tract infections like pneumonia, bronchitis, and sinusitis. Its scope and utility are defined by its efficacy in combating Gram-negative and Gram-positive pathogens resistant to other antibiotics. This creates a necessity for gemifloxacin as an advanced treatment option in settings where traditional antibiotics fail. Its applications span both pharmaceutical and healthcare sectors, particularly within hospitals and outpatient clinics. End-use includes direct prescriptions and integration into broader antimicrobial treatment regimes. Market insights indicate a robust growth trajectory driven by increasing respiratory ailment cases and a heightened focus on multi-drug resistance management. Opportunities are ripe in emerging economies where healthcare infrastructure development is on the rise, alongside expanding generic markets due to patent expirations. Research investments focusing on optimizing delivery mechanisms, such as slow-release formulations and combination therapies, represent fertile ground for business growth. However, limitations include stringent regulatory frameworks and potential adverse effects associated with fluoroquinolones, which have led to restricted use in several regions. Resistance development and competition from alternative therapeutics, like macrolides and ketolides, further challenge market expansion. Innovators could leverage genetic insights into pathogen resistance and develop personalized medicine approaches to maximize gemifloxacin's effectiveness. Additionally, market dynamics reveal a trend towards eco-friendly and sustainable manufacturing processes, presenting opportunities for business leaders to incorporate green technologies into production, thereby appealing to environmentally conscious stakeholders. Overall, navigating this market demands a strategic blend of compliance adherence, innovative research, and a keen eye on demographic health trends. With the growing incidence of respiratory diseases, particularly in aging populations, a calculated expansion into underserved regions could yield substantial returns. Adopting these measures can ensure sustained market relevance and capitalize on evolving consumer expectations and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 705.59 million
Estimated Year [2024] USD 741.01 million
Forecast Year [2030] USD 985.09 million
CAGR (%) 4.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gemifloxacin Market

The Gemifloxacin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
    • Supportive reforms in healthcare infrastructure enhancing access to antibiotics
  • Market Restraints
    • Product recalls due to safety concerns
  • Market Opportunities
    • Continuous advancements in production technologies of gemifloxacin
    • Partnerships between pharmaceutical companies and academic or research institutions
  • Market Challenges
    • Prevalence of counterfeit products and production issues

Porter's Five Forces: A Strategic Tool for Navigating the Gemifloxacin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gemifloxacin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gemifloxacin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gemifloxacin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gemifloxacin Market

A detailed market share analysis in the Gemifloxacin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gemifloxacin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gemifloxacin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gemifloxacin Market

A strategic analysis of the Gemifloxacin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gemifloxacin Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Aurobindo Pharma Limited, BASF SE, Emcure Pharmaceuticals Ltd., Hanmi Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer Inc., Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Gemifloxacin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Solution and Tablet.
  • Based on Indication, market is studied across Respiratory Infection and Urinary Tract Infection.
  • Based on Sales Channel, market is studied across Hospital Pharmacy, Online Stores, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • 5.1.1.2. Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • 5.1.2. Restraints
      • 5.1.2.1. Product recalls due to safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in production technologies of gemifloxacin
      • 5.1.3.2. Partnerships between pharmaceutical companies and academic or research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of counterfeit products and production issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • 5.2.2. Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gemifloxacin Market, by Form

  • 6.1. Introduction
  • 6.2. Solution
  • 6.3. Tablet

7. Gemifloxacin Market, by Indication

  • 7.1. Introduction
  • 7.2. Respiratory Infection
  • 7.3. Urinary Tract Infection

8. Gemifloxacin Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Stores
  • 8.4. Retail Pharmacy

9. Americas Gemifloxacin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gemifloxacin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gemifloxacin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Aurobindo Pharma Limited
  • 3. BASF SE
  • 4. Emcure Pharmaceuticals Ltd.
  • 5. Hanmi Pharmaceutical Co., Ltd.
  • 6. Hikma Pharmaceuticals PLC
  • 7. Mylan N.V.
  • 8. Orchid Chemicals & Pharmaceuticals Ltd.
  • 9. Pfizer Inc.
  • 10. Stada Arzneimittel AG
  • 11. Sun Pharmaceutical Industries Ltd.
  • 12. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GEMIFLOXACIN MARKET RESEARCH PROCESS
  • FIGURE 2. GEMIFLOXACIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GEMIFLOXACIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GEMIFLOXACIN MARKET DYNAMICS
  • TABLE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023